IP Library Granted Patent US 9,102,682
Granted Patent B2
US 9,102,682 · App. 14/452,296 · Granted Aug 11, 2015

CDK inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,102,682
App. No.
14/452,296
Granted
Aug 11, 2015
Kind
B2
Abstract

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Claims (19)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

each R 1 is independently hydrogen, aryl, alkyl, or haloalkyl, wherein each of said alkyl and haloalkyl groups optionally includes O or N heteroatoms in place of a carbon in the chain and two R 1 's on adjacent ring atoms can optionally form a 3-8-membered cycle; and

R x is halo, cyano, nitro, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkyl.

2. The compound of claim 1 having formula:

3. The compound of claim 1 having formula:

4. The compound of claim 1 having formula:

5. The compound of claim 1 , wherein R x is C 1 -C 4 alkyl.

6. The compound of claim 2 , wherein R x is C 1 -C 4 alkyl.

7. The compound of claim 3 , wherein R x is C 1 -C 4 alkyl.

8. The compound of claim 4 , wherein R x is C 1 -C 4 alkyl.

9. The compound of claim 1 , wherein R x is halogen.

10. The compound of claim 2 , wherein R x is halogen.

11. The compound of claim 3 , wherein R x is halogen.

12. The compound of claim 4 , wherein R x is halogen.

13. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the compound of claim 4 , or a pharmaceutically acceptable salt thereof.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2025
From: PHARMACOSMOS THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 071018/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2025
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 071018/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: G1 THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 069371/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 069371/0832 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 19, 2024
From: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
To: G1 THERAPEUTICS, INC.
Reel/Frame 068996/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2021
From: TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055746/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: STRUM, JAY C.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055725/0743 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 29, 2020
From: G1 THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
Reel/Frame 052795/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2016
From: STRUM, JAY C; TAVARES, FRANCIS X
To: G1 THERAPEUTICS, INC.
Reel/Frame 038521/0901 →